Only one serious adverse event occurred, an idiopathic cardiomyopathy arising 5 months after the second vaccination with 5 μg of rPA formulated with alum, but was judged to be unrelated to the vaccine. Here, RPA1 is linked to idiopathic cardiomyopathy.